Core Insights - C4 Therapeutics, Inc. (C4T) will present data from its Phase 1 clinical trial of cemsidomide for multiple myeloma at the International Myeloma Society Annual Meeting on September 20, 2025 [1][2] - The company has completed enrollment and dose escalation for the trial, which shows a well-tolerated safety profile and promising response rates [2] - An investor webcast will follow the oral presentation, providing further details on the clinical development plans [3] Company Overview - C4 Therapeutics is a clinical-stage biopharmaceutical company focused on targeted protein degradation to develop new medicines [4] - The company utilizes its TORPEDO platform to design and optimize small-molecule medicines for challenging diseases [4] - C4T's degrader medicines aim to leverage the body's natural protein recycling system to eliminate disease-causing proteins, potentially addressing drug resistance and improving patient outcomes [4] Product Information - Cemsidomide is an investigational small-molecule degrader that targets IKZF1/3, which are transcription factors involved in multiple myeloma and non-Hodgkin's lymphomas [5] - Clinical data indicates that cemsidomide is well-tolerated and shows significant anti-myeloma activity along with immunomodulatory effects [5]

Core Insights - C4 Therapeutics, Inc. reported compelling overall response rates for cemsidomide in multiple myeloma, with a 50% overall response rate (ORR) at the highest dose of 100 µg, including one patient achieving a minimal residual disease negative complete response [1][5] - The company plans to prioritize the development of cemsidomide and expects FDA feedback by mid-2025 to support the next phase of development in early 2026 [1][2] - C4T's financial position remains strong, with cash, cash equivalents, and marketable securities totaling $234.7 million as of March 31, 2025, expected to fund operations into 2027 [1][15] Cemsidomide Development - Cemsidomide's Phase 1 trial in multiple myeloma has shown a 50% ORR at the 100 µg dose level, with 80% of patients having prior CAR-T or T-cell engager therapy [5] - At the 75 µg dose level, an ORR of 40% was achieved [5] - The drug is well-tolerated with manageable neutropenia, and the ongoing Phase 1 trial for non-Hodgkin's lymphoma is still in progress [5] Financial Performance - Total revenue for Q1 2025 was $7.2 million, up from $3.0 million in Q1 2024, primarily due to collaborations with Merck KGaA and Roche [9] - Research and development expenses increased to $27.1 million in Q1 2025 from $22.5 million in Q1 2024, reflecting higher clinical trial costs [10] - General and administrative expenses decreased to $9.3 million in Q1 2025 from $10.3 million in Q1 2024 due to reduced personnel costs [11] Strategic Decisions - The company has decided not to advance CFT1946 beyond the current Phase 1 trial and will seek partnership opportunities for the BRAF program [14][18] - C4T continues to advance its internal research pipeline, focusing on targets with a strong degrader rationale applicable to various therapeutic areas [14] Upcoming Milestones - C4T plans to present data from the completed cemsidomide Phase 1 dose escalation in multiple myeloma in Q3 2025 and in non-Hodgkin's lymphoma in Q4 2025 [14] - The company aims to initiate the next phase of clinical development for cemsidomide in early 2026 [14]